Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epistem, a UK-based biotechnology and personalised medicine company, has reported revenues of £5.74m for the full year ended 30 June 2010 compared to £3.97m during the same period in 2009.
Subscribe to our email newsletter
Contract Research Services revenues grew by 10% to £2.5m against £2.3m in 2009.
Biomarker sales increased 19% year-on-year and now forms part of the newly created Personalised Medicine division.
The total comprehensive income for the financial year posted by Epistem was £290,000, or £3.3 per diluted share, compared to £83,000, or £1.0 per diluted share, for the year ago period.
Epistem chairman David Evans said that Epistem continues to build on its scientific and technical strengths as it transforms into a technology, profitable biotechnology and personalised medicine group underpinned by strong revenue growth.
“Against a backdrop of market uncertainty, Epistem remains vigilant, with the outlook for the expanding group increasingly positive,” Evans said.